Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Marc Espié"'
Autor:
Michel Marty, Marc Espié, Barbara Pistilli, Sylvie Giacchetti, Junheng Gao, Enora Laas, Sandrine Tury, F Reyal, Brice Aouchiche, Jean-Yves Pierga, E. Brain, Martin J. Edelman, Bernard Asselain, Gabriel Benchimol, Marick Laé, Xiaofei Wang, Anne-Sophie Hamy
Publikováno v:
Journal of Clinical Oncology. 37:624-635
PURPOSE The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships be
Autor:
F-C Bidard, C. Simondi, Delphine Loirat, Frédérique Berger, Véronique Diéras, J-Y Pierga, PH Cottu, William Jacot, J-M Ferrero, Thomas Bachelot, Marc Espié, Catherine Alix-Panabières, Sylvain Ladoire, Sylvain Dureau, C. Levy, H Bourgeois, Florence Dalenc, Joseph Gligorov, A. Gonçalves, E. Brain, H. Naman
Publikováno v:
Cancer Research. 79:GS3-07
Background: In ER+ HER2- metastatic breast cancer (MBC) patients, the clinical choice between 1st line hormone therapy (HT, the recommended option) or chemotherapy (CT) is based on the absence of “visceral crisis” or adverse prognostic factors, w
Autor:
Stéphanie Catala, Laetitia Gambotti, C. Faure Mercier, L. Venat-Bouvet, Xavier Pivot, Sophie Paget-Bailly, Iris Pauporté, J-M Grouin, Christelle Jouannaud, J-Y Pierga, Julie Henriques, Maria Rios, David Khayat, Gilles Romieu, P. Kerbrat, Thomas Bachelot, P. Fumoleau, Daniel Serin, Marc Espié, Marc Debled, Sophie Abadie-Lacourtoisie, J.P. Jacquin, Alain Lortholary, L. Cany
Publikováno v:
Cancer Research. 79:GS2-07
Since 2005, 12 months of trastuzumab added to chemotherapy alone is the standard of care in patients with HER2-positive breast cancer. PHARE ('Protocol for Herceptin® as Adjuvant therapy with Reduced Exposure') is the first trial comparing a reducti
Autor:
S.ophie Guillerm, Caroline Cuvier, Eva Marchand, Laurent Quero, Marc Espié, E. Bourstyn, Henri Lorphelin, Luis Augusto Teixeira, Ramona Itti, Sylvie Giacchetti, Laurence Cahen-Doidy, Christophe Hennequin, Mouna Labidi
Publikováno v:
Clinical breast cancer. 22(1)
Purpose To evaluate outcomes and post-operative toxicities after intra-operative radiotherapy (IORT) in elderly women Population Women older than 65 years, with an infiltrating ductal breast cancer ≤3 cm, expressing Estrogen receptors (ER+) without
Autor:
Jean-Yves Pierga, V. Servent, Véronique D'Hondt, Hugues Bourgeois, Véronique Diéras, William Jacot, Laurence Venat-Bouvet, Marie-Paule Sablin, Elisabeth Luporsi, Séverine Guiu, François-Clément Bidard, Frédérique Berger, Etienne Brain, Marc A. Bollet, Marc Espié, Alain Lortholary, Souhir Neffati, Coraline Dubot, Paul Cottu
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
BackgroundIn this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.MethodsMain inclusion criteria for screening were as follows: women
Autor:
Philippe Bertheau, Lucie Biard, Brigitte Poirot, Christos Sotiriou, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Matthieu Resche-Rigon, Patricia de Cremoux, Pascal Merlet, Fatiha Bouhidel, David Groheux, Marc Espié
Publikováno v:
Oncotarget
Oncotarget, 9 (23
Oncotarget, 9 (23
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic pro
Autor:
Pietrina Cottu, Christelle Jouannaud, N. Esposito, L. Dima-Martinez, Alain Lortholary, Chahinez Benkanoun, Marc Espié, V. Pottier, J-P. Spano, H. Attar-Rabia, P. Rivera, L. Moreau, Dominique Spaeth, Joseph Gligorov, Xavier Pivot, Jean-Marc Extra
Publikováno v:
European Journal of Cancer. 82:230-236
HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous (H-i.v.) and highly preferred by patients in early breast cancer. The present randomised Metasp
Autor:
Florian Scotté, Alain Toledano, Ladan Duvillié, Dominique Spaeth, Isabelle Pithois Merli, Stéphanie Perot, Elisabeth Luporsi, Roland Bugat, Marc Espié
Publikováno v:
Supportive Care in Cancer. 25:973-982
This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated c
Autor:
Ahmad Awada, Marc Espié, Miguel Martín, Mafalda Oliveira, Philippe Aftimos, Pilar Lardelli, Eva E.M. Fernández-García, Sonia Extremera, Javier Cortes, Sara López-Tarruella, Suzette Delaloge
Publikováno v:
Clinical Breast Cancer. 16:364-371
Background Preclinical and clinical data suggest that xeroderma pigmentosum G gene (XPG) status might predict trabectedin efficacy. This phase 2 study evaluated the efficacy of trabectedin at a dose of 1.3 mg/m 2 as a 3-hour intravenous infusion ever
Autor:
Marc Espié, Lina Bolotine, Jean-Charles Soria, Anne Laprie, Lucie Karayan-Tapon, Jocelyn Céraline, Henri Roché, Patricia de Cremoux, Jean-Jacques Mazeron, Sylvie Negrier, Gilles Calais, Gérard Bastian
Publikováno v:
Bulletin du Cancer. 103:719-729